China's Tianyuan Sells 85 Percent Stake To Novartis
This article was originally published in PharmAsia News
China's Zhejiang Tianyuan Bio-Pharmaceutical is selling 85 percent of the vaccine maker to Swiss drug maker Novartis
You may also be interested in...
Becton Dickinson will spend $1.2bn over the next four years to improve its drug-delivery device manufacturing capabilities. See what Eric Borin, president of BD, said about it here.
Pfizer is producing vaccine doses at scale now that it has buttoned down the manufacturing process.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.